ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)

ClinicalTrials.gov ID: NCT05383209

Public ClinicalTrials.gov record NCT05383209. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 12:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Prospective, Double-masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Sham for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)

Study identification

NCT ID
NCT05383209
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Enrollment
77 participants

Conditions and interventions

Interventions

  • EYP-1901 Drug
  • Sham IVT Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 27, 2022
Primary completion
Feb 11, 2024
Completion
May 5, 2024
Last update posted
Aug 14, 2025

2022 – 2024

United States locations

U.S. sites
36
U.S. states
19
U.S. cities
36
Facility City State ZIP Site status
EyePoint Investigative Site Phoenix Arizona 85020
EyePoint Investigative Site Huntington Beach California 92647
EyePoint Investigative Site Oxnard California 93036
EyePoint Investigative Site Palm Desert California 92211
EyePoint Investigative Site Pasadena California 90041
EyePoint Investigative Site Poway California 92064
EyePoint Investigative Site Sacramento California 95825
EyePoint Investigative Site Danbury Connecticut 06810
EyePoint Investigative Site Clearwater Florida 33761
EyePoint Investigative Site Melbourne Florida 32901
EyePoint Investigative Site Miami Florida 33143
EyePoint Investigative Site Winter Haven Florida 33880
EyePoint Investigative Site Lemont Illinois 60439
EyePoint Investigative Site Indianapolis Indiana 46290
EyePoint Investigative Site Lenexa Kansas 66215
EyePoint Investigative Site Baltimore Maryland 21209
EyePoint Investigative Site Hagerstown Maryland 21740
EyePoint Investigative Site Springfield Massachusetts 01107
EyePoint Investigative Site Reno Nevada 89502
EyePoint Investigative Site Bloomfield New Jersey 07003
EyePoint Investigative Site Toms River New Jersey 08755
EyePoint Investigative Site Great Neck New York 11021
EyePoint Investigative Site Erie Pennsylvania 16501
EyePoint Investigative Site Florence South Carolina 29501
EyePoint Investigative Site Ladson South Carolina 29456
EyePoint Investigative Site Rapid City South Dakota 57701
EyePoint Investigative Site Germantown Tennessee 38138
EyePoint Investigative Site Abilene Texas 79606
EyePoint Investigative Site Austin Texas 78705
EyePoint Investigative Site Houston Texas 78240
EyePoint Investigative Site McAllen Texas 78503
EyePoint Investigative Site Plano Texas 75075
EyePoint Investigative Site San Antonio Texas 78247
EyePoint Investigative Site The Woodlands Texas 77384
EyePoint Investigative Site Lynchburg Virginia 24502
EyePoint Investigative Site Bellevue Washington 98004

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05383209, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 14, 2025 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05383209 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →